A new study published in Circulation has found there is a 23 percent risk in reduction of all-cause mortality in non-ischemic cardiomyopathy patients with use of implantable cardioverter-defibrillator (ICD) therapy.

The American College of Cardiology recently released new guidance for clinicians and hospitals to use in assessing patients’ eligibility for transcatheter aortic valve replacement (TAVR), successfully performing the procedure and providing appropriate follow-up. The 2016 ACC Expert Consensus Decision Pathway for Transcatheter Aortic Valve Replacement in the Management of Adults with Aortic Stenosis builds on recommendations set forth in the American Heart Association (AHA)/ACC Guidelines for Management of Patients with Valvular Heart Disease.

A study led by Massachusetts General Hospital (MGH) and Icahn School of Medicine at Mount Sinai (ISSMS) investigators has linked, for the first time in humans, activity in a stress-sensitive structure within the brain to the risk of subsequent cardiovascular disease. The team's findings, being published in the journal The Lancet, also reveal a pathway leading from activation of that structure — the amygdala — through elevated immune system activity to an increased incidence of cardiovascular events.

ECRI Institute announced a new mergers and acquisitions service that empowers new hospital alliances to control their spending and plan for the future by eliminating waste and redundancy in medical-surgical supplies and capital medical equipment.

Medtronic plc announced the CE (Conformité Européenne) mark and European launch of the CoreValve Evolut R 34 mm valve — the largest sized transcatheter aortic valve implantation (TAVI) system available in Europe. The new Evolut R 34 mm valve is approved for severe aortic stenosis patients who are at intermediate, high or extreme risk for surgery with an annulus size ranging from 26-30 mm. This large valve segment is estimated to account for approximately 20-25 percent of the eligible European TAVI patient population. Previously, some of these patients were unable to receive a TAVI due to the larger size of their native diseased aortic valve.

Lumedx Corp. recently announced that it has implemented Phase 1 of a long-term, multiphase cardiovascular information system (CVIS) project with Baylor Scott & White Health.